Conference Day Two
Thursday February 27, 2025

8:00am Registration & Morning Coffee

8:50 am Chair’s Opening Remarks

  • Vladimir Bermudez Associate Director - Cell Therapies & Program Lead, Takeda Pharmaceutical Co. Ltd.

Accelerating Clinical-to-Commercial Development to Drive Yields

9:00 am Case-Study: Bridging Clinical Phase I to III Studies for Small Molecule Development to Demonstrate Quality Consistency & Safety

  • Ciby Abraham Senior Director & Group Manager - Project, Product Leadership Chemistry, Manufacturing & Controls Regulatory Affairs, AstraZeneca

Synopsis

  • Understanding how to use a bridging study to communicate process similarity to health authorities and regulators for streamlined approval
  • Outlining the use of modelling to aid bridging studies for similarity demonstrations for maximal efficiency
  • Pinpointing data and cost limitations for large biologics and using this as a decisionmaking tool to explain when is best to shift to continuous

9:30 am Leveraging Process Optimization for Cell Therapy to Enhance Speed-to Market & Efficiency

  • Vladimir Bermudez Associate Director - Cell Therapies & Program Lead, Takeda Pharmaceutical Co. Ltd.

Synopsis

  • Redefining continuous processing in the context of cell therapy for holistic clarity
  • Navigating the complexity of cell therapies during continuous manufacturing to streamline development
  • Futureproofing the cell therapy supply chain with facilities and location in mind to deliver drugs faster

10:00am Morning Coffee Break

Moving Towards Complete Integration Along the Production Line to Maximize Flexibility & Minimize Spend

10:30 am Panel Discussion: Recognizing Emerging Modalities for Continuous Manufacturing Applications to Advance Your Pipeline & Meet Demands

  • Ying Xu Head of Analytical Science, Stealth Biotech
  • Vladimir Bermudez Associate Director - Cell Therapies & Program Lead, Takeda Pharmaceutical Co. Ltd.
  • Ciby Abraham Senior Director & Group Manager - Project, Product Leadership Chemistry, Manufacturing & Controls Regulatory Affairs, AstraZeneca
  • Nolan Sutherland Associate Director, Ring Therapeutics

Synopsis

  • How are emerging modalities adapting to continuous manufacturing?
  • How must continuous manufacturing evolve as a standardized method for cell and gene therapy production?
  • Where are the gaps in transitioning from small to commercial scale for continuous manufacturing of biologics and novel modalities?

11:30 am Session Reserved for Dec Group

12:00pm Networking Lunch

Assessing Value Added for Sustainability & Green Chemistry to Meet ESG Goals

1:00 pm Exploring Pfizer’s Modular-Based Approach to Flow for Indirect API Production to Refine Your Technical & Strategic Approach

Synopsis

  •  Outlining strategy optimization when considering flow to produce starting materials in a continuous fashion
  • Addressing implementation of technologies fit for continuous flow for seamless integration
  • Quantifying sustainability measures to overcome the data scarcity bottleneck and maintain green processes

1:30 pm Roundtable Discussion: Unlocking the Future of Small Molecule Commercialization: The Role of Continuous Manufacturing

Synopsis

  •  How can continuous manufacturing streamline the development-to-commercialization timeline for small molecules, and what key challenges need to be addressed to fully leverage its potential?
  • What regulatory considerations and industry standards are critical for scaling continuous manufacturing in the small molecule sector?
  • How can continuous manufacturing improve supply chain resilience and flexibility in the commercialization of small molecules?

2:00pm Afternoon Break

Getting Ahead of the Curve: Exploration of Novel Digital Tools & Advancements for Added Layers of Efficiency

2:30 pm Applying a Cross-Modality Perspective to Advance the Manufacturing of New Drug Modalities

  • Richard Braatz Associate Faculty Director, Massachusetts Institute of Technology

Synopsis

  • Understanding how to leverage synthetic molecule techniques for biologics to facilitate progression for newer modalities
  • Applying rationale for continuous crystallization of small molecule to biologics continuous processing to tap into uncovered opportunities
  • Addressing the mindset and skillset required to apply from small molecule to biologics to shorten time to market for all therapeutics 

3:00 pm Exploring Membrane-Based Antisolvent Crystallization for Nanocrystals in Continuous API Manufacturing

  • Kamalesh K . Sirkar Distinguished Professor, Chemical Engineering, New Jersey Institute of Technology

Synopsis

 Leveraging membrane-based antisolvent crystallization to continuously produce nanocrystals of various APIs

• How membrane technology can support a streamlined, scalable, and sustainable API production process for API nanocrystals

• Eliminates milling processes to obtain nanocrystals from microcrystals and minimizes operational challenges in pharmaceutical manufacturing

3:30 pm Working With Digital Twins to Improve Continuous Manufacturing & Explore Future Industry Potential

  • Jared Auclair Director of Bioinnovation, Northeastern University

Synopsis

  • Outlining how to begin implementation of digital twin-aided continuous manufacturing to direct real-time processes with minimal error
  • Exploring challenges and opportunities in digital twin data management to increase accuracy and efficiency
  • Exploring potential industry applications for digital twins paired with continuous manufacturing to shed light on innovation 

4:00 pm Chair’s Closing Remarks & End of Conference

  • Vladimir Bermudez Associate Director - Cell Therapies & Program Lead, Takeda Pharmaceutical Co. Ltd.